Table S3. DKK3 deregulation reported in different tumors and its therapeutic potential.

Tumor	Reported function	Selected evidence for therapeutic potential	References
Breast cancer	Tumor suppressor	Diagnostic factor	[1]
		Prognostic factor	[2–7]
		In vitro proliferation	[3,4,8]
		In vitro migration/invasion	[3,8]
		In vivo tumor growth	[8]
Gastric cancer	Tumor suppressor	Prognostic factor	[7,9–13]
		In vitro proliferation	[13]
		In vitro migration/invasion	[13]
Glioma/Glioblastoma	Tumor suppressor	Prognostic factor	[14]
		In vitro proliferation	[14–18]
		In vivo tumor growth	[15–18]
Leukemia	Tumor suppressor	Prognostic factor	[19]
Medulloblastoma	Tumor suppressor	Prognostic factor	[20]
Neuroblastoma	Tumor suppressor	Prognostic factor	[21,22]
		In vitro proliferation	[21]
Osteosarcoma	Tumor suppressor	*In vitro* proliferation	[23]
		In vitro migration/invasion	[23,24]
		In vivo tumor growth	[23]
Ovarian cancer	Tumor suppressor	Prognostic factor	[7,25–27]
		In vitro proliferation	[28]
Renal cell Carcinoma	Tumor suppressor	Diagnostic factor	[29,30]
		In vitro proliferation	[31,32]
		In vivo proliferation	[31]
Thyroid cancer	Tumor suppressor	Prognostic factor	[33]
Bladder cancer	Oncogene	*In vitro* proliferation	[34]
	Tumor suppressor	Diagnostic factor	[35]
		Prognostic factor	[35,36]
		In vitro proliferation	[37–40]
		In vitro migration/invasion	[36]
Cervical cancer	Oncogene	Prognostic factor	[25]
	Tumor suppressor	Prognostic factor	[41–44]
		In vitro proliferation	[42,43]
		In vitro migration/invasion	[43]
Colorectal cancer	Oncogene	Prognostic factor	[45]
	Tumor suppressor	Diagnostic factor	[46]
		Prognostic factor	[46,47]
		In vitro proliferation	[48]
		In vitro migration/invasion	[48]
Endometrial carcinoma	Oncogene	Prognostic factor	[25]
	Tumor suppressor	Prognostic factor	[41,49,50]
		In vitro proliferation	[49]
		In vitro migration/invasion	[49]
		In vivo tumor growth	[49]
Esophageal carcinoma	Oncogene	Prognostic factor	[51–53]
		In vitro proliferation	[52]
		In vitro migration/invasion	[51]
		In vivo tumor growth	[51,52]
	Tumor suppressor	Prognostic factor	[54]

Head and neck carcinoma	Oncogene	Diagnostic factor	[55]
		Prognostic factor	[56–59]
		In vitro proliferation	[60,61]
		In vitro migration/invasion	[60–62]
		In vivo tumor growth	[60,61]
	Tumor suppressor	Diagnostic factor	[63,64]
Hepatocellular carcinoma	Oncogene	Diagnostic factor	[65–67]
		Prognostic factor	[66]
		In vitro proliferation	[68]
		In vivo tumor growth	[68]
	Tumor suppressor	Diagnostic factor	[69,70]
		Prognostic factor	[70–72]
		In vitro proliferation	[73]
		In vivo tumor growth	[73]
Lung cancer	Oncogene	Prognostic factor	[7,74]
		In vitro proliferation	[74]
		In vitro migration/invasion	[74]
	Tumor suppressor	Prognostic factor	[75,76]
		In vitro proliferation	[76–79]
		In vitro migration/invasion	[78]
		In vivo tumor growth	[78,79]
Melanoma/skin cancer	Oncogene	*In vivo* tumor growth	[80]
	Tumor suppressor	Prognostic factor	[81–83]
		In vitro proliferation	[82]
		In vitro migration/invasion	[81,82]
		In vivo tumor growth	[81,82]
Pancreatic cancer	Oncogene	Prognostic factor	[84]
		In vitro proliferation	[84]
		In vitro migration/invasion	[84]
		In vivo tumor growth	[84]
	Tumor suppressor	Diagnostic factor	[85,86]
		Prognostic factor	[87]
		In vitro proliferation	[85–89]
		In vitro migration/invasion	[85]
		In vivo tumor growth	[85,86,88]
Prostate cancer	Oncogene	Diagnostic factor	[90]
		In vitro proliferation	[91]
	Tumor suppressor	Diagnostic factor	[92]
		Prognostic factor	[92–95]
		In vitro proliferation	[94–99]
		In vitro migration/invasion	[94,96,100,101]
		In vivo tumor growth	[98,99,101]

REFERENCES SUPPLEMENTARY TABLE 3

1. Kloten, V. *et al.* Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. *Breast Cancer Res.* (2013) doi:10.1186/bcr3375.

2. Hayashi, T. *et al.* DNA methylation status of REIC/Dkk-3 gene in human malignancies. *J. Cancer Res.*

Clin. Oncol. **138**, 799–809 (2012).

3. Xiang, T. *et al.* Epigenetic silencing of the WNT antagonist Dickkopf 3 disrupts normal Wnt/β-catenin signalling and apoptosis regulation in breast cancer cells. *J. Cell. Mol. Med.* **17**, 1236–1246 (2013).

4. Lorsy, E. *et al.* Loss of Dickkopf 3 promotes the tumorigenesis of basal breast cancer. *PLoS One* **11**, e0160077 (2016).

5. Veeck, J. *et al.* Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. *BMC Cancer* **9**, 217 (2009).

6. Veeck, J. *et al.* Wnt signalling in human breast cancer: Expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours. *Breast Cancer Res.* **10**, R82 (2008).

7. Chen, G. Y. & Zheng, H. C. The clinicopathological and prognostic significances of Dkk3 expression in cancers: A bioinformatics analysis. *Cancer Biomarkers* (2018) doi:10.3233/CBM-181245.

8. Kawasaki, K. *et al.* REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer. *Cancer Gene Ther.* **16**, 65–72 (2009).

9. Park, J.-M. M. *et al.* Aberrant loss of Dickkopf-3 in gastric cancer: Can it predict lymph node metastasis preoperatively? *World J. Surg.* **39**, 1018–1025 (2015).

10. Yu, J. *et al.* Promoter methylation of the Wnt/β-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. *Cancer* **115**, 49–60 (2009).

11. Yang, H. J. *et al.* Helicobacter pylori-induced modulation of the promoter methylation of Wnt antagonist genes in gastric carcinogenesis. *Gastric Cancer* (2018) doi:10.1007/s10120-017-0741-6.

12. Kishino, T. *et al.* Integrated analysis of DNA methylation and mutations in esophageal squamous cell carcinoma. *Mol. Carcinog.* **55**, 2077–2088 (2016).

13. Xu, X. Y. *et al.* The roles of REIC gene and its encoding product in gastric carcinoma. *Cell Cycle* (2012) doi:10.4161/cc.19823.

14. Mizobuchi, Y. *et al.* REIC/Dkk-3 induces cell death in human malignant glioma. *Neuro. Oncol.* **10**, 244–253 (2008).

15. Oka, T. *et al.* A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy. *Sci. Rep.* **6**, 33319 (2016).

16. Shimazu, Y. *et al.* Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma. *Gene Ther.* **22**, 146–154 (2015).

17. Fujihara, T. *et al.* Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model. *J. Neurooncol.* (2018) doi:10.1007/s11060-018-2894-5.

18. Hara, K. *et al.* Blocking of the interaction between Wnt proteins and their co-receptors contributes to the anti-tumor effects of adenovirus-mediated DKK3 in glioblastoma. *Cancer Lett.* (2015) doi:10.1016/j.canlet.2014.09.045.

19. Roman-Gomez, J. *et al.* Transcriptional silencing of the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia. *Br. J. Cancer* **91**, 707–713 (2004).

20. Valdora, F. *et al.* Epigenetic silencing of DKK3 in medulloblastoma. *Int. J. Mol. Sci.* **14**, 7492–7505 (2013).

21. Koppen, A. *et al.* Dickkopf-3 expression is a marker for neuroblasts tumor maturation and is down-regulated by MYCN. *Int. J. Cancer* **122**, 1455–1464 (2008).

22. Revet, I. *et al.* MSX1 induces the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3. *Cancer Lett.* (2010) doi:10.1016/j.canlet.2009.08.019.

23. Lin, C. H. *et al.* Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma. *Sarcoma* (2013) doi:10.1155/2013/147541.

24. Hoang, B. H. *et al.* Dickkopf 3 Inhibits Invasion and Motility of Saos-2 Osteosarcoma Cells by Modulating the Wnt-β-Catenin Pathway. *Cancer Res.* **64**, 2734–2739 (2004).

25. Jiang, T., Huang, L., Wang, S. & Zhang, S. Clinical significance of serum Dkk-3 in patients with gynecological cancer. *J. Obstet. Gynaecol. Res.* **36**, 769–773 (2010).

26. You, A. *et al.* Expression of the Wnt antagonist DKK3 is frequently suppressed in sporadic epithelial ovarian cancer. *J. Cancer Res. Clin. Oncol.* **137**, 621–627 (2011).

27. Xu, Y. *et al.* Hypermethylation of CDH13, DKK3 and FOXL2 promoters and the expression of EZH2 in ovary granulosa cell tumors. *Mol. Med. Rep.* **14**, 2739–2745 (2016).

28. Takata, A. *et al.* Dkk-3 induces apoptosis through mitochondrial and fas death receptor pathways in human mucinous ovarian cancer cells. *Int. J. Gynecol. Cancer* **25**, 372–379 (2015).

29. Guo, C. C. *et al.* Decreased expression of Dkk1 and Dkk3 in human clear cell renal cell carcinoma. *Mol. Med. Rep.* **9**, 2367–2373 (2014).

30. Kurose, K. *et al.* Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma. *J. Urol.* **171**, 1314–1318 (2004).

31. Ueno, K. *et al.* Wnt antagonist DICKKOPF-3 (Dkk-3) induces apoptosis in human renal cell carcinoma. *Mol. Carcinog.* **50**, 449–457 (2011).

32. Xu, J. *et al.* Exogenous DKK-3/REIC inhibits Wnt/β-catenin signaling and cell proliferation in human kidney cancer KPK1. *Oncol. Lett.* **14**, 5638–5642 (2017).

33. Yin, D. T. *et al.* DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma. *Endocr. Relat. Cancer* **20**, 507–514 (2013).

34. Tsujimura, N. *et al.* A novel role of dickkopf-related protein 3 in macropinocytosis in human bladder cancer T24 cells. *Int. J. Mol. Sci.* **17**, 1846 (2016).

35. Urakami, S. *et al.* Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. *Clin. Cancer Res.* **12**, 2109–2116 (2006).

36. Ning, J., Yu, W., Cheng, F., Rao, T. & Ruan, Y. MiR-425 Promotes Migration and Invasion in Bladder Cancer by Targeting Dickkopf 3. *J. Cancer* (2020) doi:10.7150/jca.40233.

37. Hirata, T. *et al.* REIC/Dkk-3-encoding adenoviral vector as a potentially effective therapeutic agent for bladder cancer. *Int. J. Oncol.* **41**, 559–564 (2012).

38. Jin, Y. *et al.* Partial sensitization of human bladder cancer cells to a gene-therapeutic adenovirus carrying REIC/Dkk-3 by downregulation of BRPK/PINK1. *Oncol. Rep.* (2012) doi:10.3892/or.2011.1543.

39. Kobayashi, T. *et al.* Mechanistic analysis of resistance to REIC/Dkk-3-induced apoptosis in human bladder cancer cells. *Acta Med. Okayama* **62**, 393–401 (2008).

40. Horikawa, Y. *et al.* Overexpression of REIC/Dkk-3 suppresses the expression of CD147 and inhibits the proliferation of human bladder cancer cells. *Oncol. Lett.* **14**, 3223–3228 (2017).

41. Ryu, S. W. *et al.* Reduced expression of DKK3 is associated with adverse clinical outcomes of uterine cervical squamous cell carcinoma. *Int. J. Gynecol. Cancer* **23**, 134–140 (2013).

42. Lee, E. J. *et al.* Dkk3, downregulated in cervical cancer, functions as a negative regulator of β-catenin. *Int. J. Cancer* **124**, 287–297 (2009).

43. Luo, S. *et al.* MicroRNA-92a promotes cell viability and invasion in cervical cancer via directly targeting Dickkopf-related protein 3. *Exp. Ther. Med.* **14**, 1227–1234 (2017).

44. Kang, W. S. *et al.* Clinico-epigenetic combination including quantitative methylation value of DKK3 augments survival prediction of the patient with cervical cancer. *J. Cancer Res. Clin. Oncol.* (2013) doi:10.1007/s00432-012-1262-7.

45. Zitt, M. *et al.* Dickkopf-3 as a new potential marker for neoangiogenesis in colorectal cancer: expression in cancer tissue and adjacent non-cancerous tissue. *Dis. Markers* **24**, 101–9 (2008).

46. Safari, E., Mosayebi, G. & Khorrami, S. Dkk-3 as a potential biomarker for diagnosis and prognosis of colorectal cancer. *Med. J. Islam. Repub. Iran* (2018) doi:10.14196/mjiri.32.86.

47. Voorham, Q. J. M. *et al.* Promoter methylation of Wnt-antagonists in polypoid and nonpolypoid colorectal adenomas. *BMC Cancer* (2013) doi:10.1186/1471-2407-13-603.

48. Yang, Z. R., Dong, W. G., Lei, X. F., Liu, M. & Liu, Q. S. Overexpression of Dickkopf-3 induces apoptosis through mitochondrial pathway in human colon cancer. *World J. Gastroenterol.* **18**, 1590–1601 (2012).

49. Dellinger, T. H. *et al.* Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer. *Gynecol. Oncol.* **126**, 259–267 (2012).

50. Eskander, R. N. *et al.* Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. in *International Journal of Gynecological Cancer* vol. 26 125–132 (2016).

51. Wang, Z. *et al.* The role of Dickkopf-3 overexpression in esophageal adenocarcinoma. *J. Thorac. Cardiovasc. Surg.* **150**, 377-385.e2 (2015).

52. Kajiwara, C. *et al.* P63-dependent Dickkopf3 expression promotes esophageal cancer cell proliferation via CKAP4. *Cancer Res.* (2018) doi:10.1158/0008-5472.CAN-18-1749.

53. McLaren, P. J. *et al.* Specific gene expression profiles are associated with a pathologic complete response to neoadjuvant therapy in esophageal adenocarcinoma. in *American Journal of Surgery* (2017). doi:10.1016/j.amjsurg.2017.03.024.

54. Liu, J. Bin *et al.* Plasma DNA methylation of Wnt antagonists predicts recurrence of esophageal squamous cell carcinoma. *World J. Gastroenterol.* (2011) doi:10.3748/wjg.v17.i44.4917.

55. Zhang, C. *et al.* Expression pattern of DKK3, dickkopf WNT signaling pathway inhibitor 3, in the malignant progression of oral submucous fibrosis. *Oncol. Rep.* (2017) doi:10.3892/or.2016.5307.

56. Katase, N. *et al.* Deletion at Dickkopf (Dkk)-3 locus (11p15.2) is related with lower lymph node metastasis and better prognosis in head and neck squamous cell carcinomas. *Oncol. Res.* **17**, 273–282 (2008).

57. Katase, N., Nagano, K. & Fujita, S. DKK3 expression and function in head and neck squamous cell carcinoma and other cancers. *Journal of Oral Biosciences* (2020) doi:10.1016/j.job.2020.01.008.

58. Katase, N. *et al.* Absence of Dickkopf (Dkk)-3 protein expression is correlated with longer disease-free survival and lower incidence of metastasis in head and neck squamous cell carcinoma. *Oncol. Lett.* (2012) doi:10.3892/ol.2011.473.

59. Fujii, M. *et al.* Dickkopf (Dkk)-3 and β-catenin expressions increased in the transition from normal oral mucosal to oral squamous cell carcinoma. *J. Mol. Histol.* (2011) doi:10.1007/s10735-011-9357-z.

60. Katase, N. *et al.* DKK3 Overexpression Increases the Malignant Properties of Head and Neck Squamous Cell Carcinoma Cells. *Oncol. Res. Featur. Preclin. Clin. Cancer Ther.* **26**, 45–58 (2017).

61. Katase, N., Nishimatsu, S. I., Yamauchi, A., Yamamura, M. & Fujita, S. DKK3 knockdown confers negative effects on the malignant potency of head and neck squamous cell carcinoma cells via the PI3K/Akt and MAPK signaling pathways. *Int. J. Oncol.* (2019) doi:10.3892/ijo.2018.4667.

62. Katase, N. *et al.* Knockdown of Dkk-3 decreases cancer cell migration and invasion independently of the Wnt pathways in oral squamous cell carcinoma-derived cells. *Oncol. Rep.* **29**, 1349–1355 (2013).

63. Pannone, G. *et al.* WNT pathway in oral cancer: Epigenetic inactivation of WNT-inhibitors. *Oncol. Rep.* **24**, 1035–1041 (2010).

64. Al-Dhohrah, T., Mashrah, M., Yao, Z. & Huang, J. Aberrant DKK3 expression in the oral leukoplakia and oral submucous fibrosis: A comparative immunohistochemical study. *Eur. J. Histochem.* (2016) doi:10.4081/ejh.2016.2629.

65. Erdal, H. *et al.* Combination of DKK1 and AFP improves diagnostic accuracy of hepatocellular carcinoma compared with either marker alone. *Turkish J. Gastroenterol.* **27**, 375–381 (2016).

66. Li, X. *et al.* In-depth analysis of secretome and N-glycosecretome of human hepatocellular carcinoma metastatic cell lines shed light on metastasis correlated proteins. *Oncotarget* (2016) doi:10.18632/oncotarget.8247.

67. Pei, Y. *et al.* Overexpression of Dickkopf 3 in hepatoblastomas and hepatocellular carcinomas. *Virchows Arch.* **454**, 639–646 (2009).

68. Pei, Y. *et al.* GATA4 promotes hepatoblastoma cell proliferation by altering expression of miR125b and DKK3. *Oncotarget* **7**, 77890–77901 (2016).

69. Liang, L. *et al.* Preliminary mechanism on the methylation modification of Dkk-1 and Dkk-3 in hepatocellular carcinoma. *Tumor Biol.* **36**, 1245–1250 (2015).

70. Ding, Z., Qian, Y. Ben, Zhu, L. X. & Xiong, Q. R. Promoter methylation and mRNA expression of DKK-3 and WIF-1 in hepatocellular carcinoma. *World J. Gastroenterol.* **15**, 2595–2601 (2009).

71. Jee, B. A. *et al.* Dynamics of genomic, epigenomic, and transcriptomic aberrations during stepwise hepatocarcinogenesis. *Cancer Res.* (2019) doi:10.1158/0008-5472.CAN-19-0991.

72. Yang, B. *et al.* Methylation of Dickkopf-3 as a prognostic factor in cirrhosis-related hepatocellular carcinoma. *World J. Gastroenterol.* **16**, 755–763 (2010).

73. Hsieh, S. Y., Hsieh, P. S., Chiu, C. T. & Chen, W. Y. Dickkopf-3/REIC functions as a suppressor gene of tumor growth. *Oncogene* **23**, 9183–9189 (2004).

74. Komori, Y. *et al.* Dickkopf-related protein 3 promotes cell adhesion and invasion during progression of lung adenocarcinoma. *Pathol. Int.* (2019) doi:10.1111/pin.12863.

75. Nozaki, I. *et al.* Reduced expression of REIC/Dkk-3 gene in non-small cell lung cancer. *Int. J. Oncol.* **19**, 117–121 (2001).

76. Yue, W. *et al.* Downregulation of Dkk3 activates β-catenin/TCF-4 signaling in lung cancer. *Carcinogenesis* **29**, 84–92 (2008).

77. Tao, L., Huang, G., Chen, Y. & Chen, L. DNA methylation of DKK3 modulates docetaxel chemoresistance in human nonsmall cell lung cancer cell. *Cancer Biother. Radiopharm.* **30**, 100–106 (2015).

78. Wang, Z., Ma, L. J., Kang, Y., Li, X. & Zhang, X. J. Dickkopf-3 (Dkk3) induces apoptosis in cisplatin-resistant lung adenocarcinoma cells via the Wnt/β-catenin pathway. *Oncol. Rep.* **33**, 1097–1106 (2015).

79. Shien, K. *et al.* Anti-cancer effects of REIC/Dkk-3-encoding adenoviral vector for the treatment of non-small cell lung cancer. *PLoS One* **9**, e87900 (2014).

80. Lu, K. H. *et al.* Dickkopf-3 contributes to the regulation of anti-tumor immune responses by mesenchymal stem cells. *Front. Immunol.* (2015) doi:10.3389/fimmu.2015.00645.

81. Kuphal, S. *et al.* Expression of Dickkopf genes is strongly reduced in malignant melanoma. *Oncogene* **25**, 5027–5036 (2006).

82. Shin, J. M. *et al.* The expression pattern and functional role of REIC/Dkk-3 in the development of cutaneous squamous cell carcinoma. *J. Dermatol. Sci.* **84**, 88–96 (2016).

83. Du, G. *et al.* Expression of REIC/Dkk-3 in normal and hyperproliferative epidermis. *Exp. Dermatol.* (2011) doi:10.1111/j.1600-0625.2010.01244.x.

84. Zhou, L. *et al.* Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. *Sci. Transl. Med.* (2018) doi:10.1126/scitranslmed.aat3487.

85. Guo, Q. & Qin, W. DKK3 blocked translocation of β-catenin/EMT induced by hypoxia and improved gemcitabine therapeutic effect in pancreatic cancer Bxpc-3 cell. *J. Cell. Mol. Med.* **19**, 2832–2841 (2015).

86. Uchida, D. *et al.* Potential of adenovirus-mediated REIC/Dkk-3 gene therapy for use in the treatment of pancreatic cancer. *J. Gastroenterol. Hepatol.* **29**, 973–983 (2014).

87. Fong, D. *et al.* Dkk-3 expression in the tumor endothelium: A novel prognostic marker of pancreatic adenocarcinomas. *Cancer Sci.* **100**, 1414–1420 (2009).

88. Sawahara, H. *et al.* Novel REIC/Dkk-3-encoding adenoviral vector as a promising therapeutic agent for pancreatic cancer. *Cancer Gene Ther.* **23**, 278–283 (2016).

89. Gu, Y. M., Ma, Y. H., Zhao, W. G. & Chen, J. Dickkopf3 Overexpression inhibits pancreatic cancer cell growth in vitro. *World J. Gastroenterol.* **17**, 3810–3817 (2011).

90. Zenzmaier, C. *et al.* Elevated levels of Dickkopf-related protein 3 in seminal plasma of prostate cancer patients. *J. Transl. Med.* **9**, 193 (2011).

91. Zenzmaier, C., Sampson, N., Plas, E. & Berger, P. Dickkopf-related protein 3 promotes pathogenic stromal remodeling in benign prostatic hyperplasia and prostate cancer. *Prostate* **73**, 1441–1452 (2013).

92. Kim, M. S., Lee, H. N., Kim, H. J. & Myung, S. C. Single nucleotide polymorphisms in DKK3 gene are associated with prostate cancer risk and progression. *Int. Braz J Urol* (2015) doi:10.1590/S1677-5538.IBJU.2014.0041.

93. Kamińska, K., Białkowska, A., Kowalewski, J., Huang, S. & Lewandowska, M. A. Differential gene methylation patterns in cancerous and non-cancerous cells. *Oncol. Rep.* (2019) doi:10.3892/or.2019.7159.

94. Al Shareef, Z. *et al.* Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1. *Oncogene* **37**, 5305–5324 (2018).

95. Kawano, Y. *et al.* Regulation of prostate cell growth and morphogenesis by Dickkopf-3. *Oncogene* **25**, 6528–6537 (2006).

96. Kardooni, H. *et al.* CRISPR-mediated reactivation of DKK3 expression attenuates TGF-β signaling in prostate cancer. *Cancers (Basel).* **10**, 165 (2018).

97. Mori, A. *et al.* The downregulation of the expression of CD147 by tumor suppressor REIC/Dkk-3, and its implication in human prostate cancer cell growth inhibition. *Acta Med. Okayama* (2017)

doi:10.18926/AMO/54982.

98. Romero, D. *et al.* Downregulation of Dickkopf-3 disrupts prostate acinar morphogenesis through TGF-β/smad signalling. *J. Cell Sci.* (2013) doi:10.1242/jcs.119388.

99. Chen, J. *et al.* REIC/Dkk-3 stable transfection reduces the malignant phenotype of mouse prostate cancer RM9 cells. *Int. J. Mol. Med.* (2009) doi:10.3892/ijmm_00000293.

100. Romero, D. *et al.* Dickkopf-3 regulates prostate epithelial cell acinar morphogenesis and prostate cancer cell invasion by limiting TGF-β-dependent activation of matrix metalloproteases. *Carcinogenesis* **37**, 18–29 (2016).

101. Edamura, K. *et al.* Adenovirus-mediated REIC/Dkk-3 gene transfer inhibits tumor growth and metastasis in an orthotopic prostate cancer model. *Cancer Gene Ther.* **14**, 765–772 (2007).